by Karl PapadoupulosApril 22, 2012
(HYGS, HLX, ACHN) PennyOmega.com Watch List for Monday Apr. 23, 2012
HYGS, Hydrogenics Corporation
** HYGS reported that it has entered into an agreement with Enbridge Inc. to jointly develop utility scale energy storage in North America.
This relationship also includes an equity investment of CA$5.0 million in HYGS . The collaboration will bring together HYGS ' expertise in water electrolysis with Enbridge's expertise in the ownership and operation of natural gas pipeline networks and renewable energy generation.
The parties will work together to develop utility scale energy storage projects within Enbridge's North American footprint. HYGS will have the opportunity to participate in up to 50% ownership in a build own operate model for energy storage services.
With 'Power-to-Gas', the hydrogen produced during periods of excess renewable generation will be injected into the existing natural gas pipeline network, proportionally increasing the renewable energy content in natural gas pipelines for essentially the operating cost of the electrolyzer.
Small quantities of hydrogen can be manageable in existing natural gas pipeline networks. With the significant scale of the natural gas pipeline network, these same quantities of hydrogen have a very meaningful impact on electricity energy storage potential.
The natural gas pipeline network represents a vast energy storage system which already exists. The utility scale energy storage leverages existing natural gas pipeline and storage assets to enable improved operability for the electrical system.
The collaboration between HYGS and Enbridge will initially focus on the deployment of utility scale energy storage in Ontario with the opportunity to expand into Enbridge's operations elsewhere.
HYGS is a globally recognized developer and provider of hydrogen generation and fuel cell products and services, serving the growing industrial and clean energy markets of today and tomorrow.
More about HYGS at www.hydrogenics.com
HLX, Helix Energy Solutions Group, Inc.
** For the first quarter of 2012, HLX posted net income of $65.7 million, or $0.62 per diluted share, compared with net income of $25.9 million, or $0.24 per diluted share, in the same period the prior year, and net income of $16.8 million, or $0.16 per diluted share in the previous quarter.
HLX is an international offshore energy company that provides development solutions and other key life of field services to the open energy market as well as to our own oil and gas business unit.
More about HLX at www.HelixESG.com
ACHN, Achillion Pharmaceuticals, Inc.
** ACHN reported that in the second segment of its Phase 2a trial of ACH-1625, 94 - 100% of patients with treatment naive genotype 1 chronic hepatitis C virus (HCV) achieved a complete early virologic response (cEVR) after 12 weeks of treatment with ACH-1625 in combination with pegylated interferon alfa-2a and ribavirin (P/R). ACH-1625 in combination with P/R for up to 12 weeks was safe and well tolerated and produced high viral response rates regardless of dose level or IL28B genotype status.
Results from this trial were presented during the 47th Annual Meeting of the European Association for the Study of the Liver (EASL) International Liver Congress 2012 in Barcelona, Spain from April 18 -- 22, 2012. Additional posters detailing ACHN 's NS5A inhibitor program, including ACH-2928 and ACH-3102, were also presented during EASL.
The hepatitis C virus is the most common cause of viral hepatitis, which is an inflammation of the liver. It is currently estimated that more than 170 million people are infected with HCV worldwide including nearly 4 million people in the United States, more than twice as widespread as HIV.
ACHN is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. ACHN is focused on solutions for the most challenging problems in infectious disease including hepatitis C and resistant bacterial infections.
More about ACHN at www.achillion.com
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( Read more at http://pennyomega.com/disclaimer ). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
News Source: http://www.free-press-release.com/news-hygs-hlx-achn-pennyomega-com-watch-list-for-monday-apr-23-2012-1335137501.html
In Her Latest Webinar, Sue Clement, Marketing Strategist and Referral Expert Shares The 3 Key Roadblocks That Keep Business Owners And Solo Professionals From Getting More Clients.
Angelina Jolie says that she has had a preventive double mastectomy after learning she carried a gene that made it extremely likely she would get breast cancer.